UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy
Alcon Research, LLC · Decision date Aug 26, 2024
What did the FDA approve?
The FDA approved UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System on August 26, 2024. Both are indicated for intraocular injection for uncomplicated retinal detachments. The UNIFEYE system lists vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange as associated measures. The UNIPEXY system lists the same associated measures except air/gas exchange.
The applicant is Alcon Research, LLC. The device category is gases used within the eye to place pressure on a detached retina, with product code LPO and specialty ophthalmic. The source statement reports the intended use as submitted; it does not independently establish safety or clinical effectiveness. No supplement type or reason is recorded.
FDA approval order statement
Approval for UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System. The UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange.The UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, and laser photocoagulation.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Aug 26, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230012
- Regulatory pathway
- Premarket approval application
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- Decision code
- APPR
- Decision date
- Aug 26, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gases used within eye to place pressure on detached retina.
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230012 received
Application receipt date recorded by FDA.
P230012 · FDA decision
APPR
P230012/S012 · Related supplement
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System
Timeline entries are records held by MedtechLedger for P230012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LPO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA approval | Jul 2, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Research, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 20511 Lake Forest Dr., Lake Forest, CA, 92630
Sources and methodology
- Original FDA record: P230012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

